Literature DB >> 3768876

Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.

B M Cantwell, M Earnshaw, A L Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3768876

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.

Authors:  B M Cantwell; C R Franks; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.

Authors:  G Falkson; M Hunt; E C Borden; J A Hayes; C I Falkson; T J Smith
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

Review 4.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

5.  Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.

Authors:  A A Ermens; J Lindemans; J Abels
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.